Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Total Current Liabilities (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Total Current Liabilities for 10 consecutive years, with $384.0 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 11.63% to $384.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $384.0 million through Dec 2025, up 11.63% year-over-year, with the annual reading at $384.0 million for FY2025, 11.63% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $384.0 million at Ultragenyx Pharmaceutical, up from $340.0 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $384.0 million in Q4 2025, with the low at $127.0 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $245.1 million, with a median of $249.8 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities plummeted 35.46% in 2021, then soared 73.64% in 2022.
  • Over 5 years, Total Current Liabilities stood at $181.4 million in 2021, then skyrocketed by 44.02% to $261.2 million in 2022, then rose by 7.36% to $280.4 million in 2023, then rose by 22.67% to $344.0 million in 2024, then grew by 11.63% to $384.0 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $384.0 million, $340.0 million, and $293.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.